Immunologic Effect and Tolerability of Intra-Seasonal Subcutaneous Immunotherapy With an 8-Day Up-Dosing Schedule to 10,000 Standardized Quality-Units: A Double-Blind, Randomized, Placebo-Controlled Trial

Clinical Therapeutics

Volumn 34, Issue 10, 2012, Pages 2072-2081

  Pfaar, Oliver ^a   Wolf, Hendrik ^b   Klimek, Ludger ^a   Schnitker, Jörg ^c   Wüstenberg, Eike ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b ALK Arzneimittel GmbH   (Germany)

^c Institut für Angewandte Statistik IAS   (Germany)

Author keywords

6 grass mix and rye; Allergic rhinoconjunctivitis; Intra seasonal up dosing; Safety; Subcutaneous immunotherapy (SCIT)

Indexed keywords

ALUTARD; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G4; PLACEBO;

ADULT; ARTICLE; AVENA ELATIOR; BINDING AFFINITY; CONTROLLED STUDY; DACTYLIS; DACTYLIS GLOMERATA; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; FESTUCA PRATENSIS; GRASS POLLEN; HAY FEVER; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERENNIAL RYEGRASS; PHASE 3 CLINICAL TRIAL; PHLEUM PRATENSE; POA PRATENSIS; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RYE; STANDARDIZATION; SUBCUTANEOUS IMMUNOTHERAPY;

ADOLESCENT; ADULT; AGED; ALLERGENS; CONJUNCTIVITIS, ALLERGIC; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOTHERAPY; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PLANT EXTRACTS; POACEAE; POLLEN; PRACTICE GUIDELINES AS TOPIC; RHINITIS, ALLERGIC, SEASONAL; SEASONS; SECALE CEREALE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84867346680     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.09.006     Document Type: Article

References (24)

1. Bousquet J., Khaltaev N., Cruz A.A., et al. Allergic Rhinitis and its Impact on Asthma (ARIA), 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008, 63(Suppl 86):8-160.
2. Bousquet J., Van Cauwenberge P., Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001, 108(Suppl 5):S147-S334. Aria Workshop Group; World Health Organization.
3. Alvarez-Cuesta E., Bousquet J., Canonica G.W., et al. Standards for practical allergen-specific immunotherapy. Allergy 2006, 61(Suppl 82):1-20. EAACI, Immunotherapy Task Force.
4. Ott H., Sieber J., Brehler R., et al. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study. Allergy 2009, 64:1394-1401.
5. Reich K., Gessner C., Kroker K., et al. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis. Clin Ther 2011, 33:828-840.
6. Cox L. Accelerated immunotherapy schedules: review of efficacy and safety. Ann Allergy Asthma Immunol 2006, 97:126-137.
7. Pfaar O., Leitzbach S., Hormann K., Klimek L. Cluster protocols in SCIT: enough evidence for practical use?. Curr Opin Allergy Clin Immunol 2010, 10:188-193.
8. Frew A.J., Powell R.J., Corrigan C.J., Durham S.R. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006, 117:319-325.
9. Bufe A., Eberle P., Franke-Beckmann E., et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol 2009, 123:167-173.
10. Pfaar O., Jung K., Wolf H., et al. Immunological effects and tolerability of a new fast updosed immunologically enhanced subcutaneous immunotherapy formulation with optimised allergen/adjuvant ratio. Allergy 2012, 67:630-637.
11. Klimek L., Wolf H., Mewes T., et al. The effect of short-term immunotherapy with molecular standardized grass and rye allergens on eosinophil cationic protein and tryptase in nasal secretions. J Allergy Clin Immunol 1999, 103:47-53.
12. Machin D., Campbell M., Fayers P., Pinol A. Sample Size Tables for Clinical Studies 1997, Blackwell Science Ltd, Oxford, United Kingdom. 2nd ed.
13. Powell R.J., Frew A.J., Corrigan C.J., Durham S.R. Effect of grass pollen immunotherapy with Alutard SQ on quality of life in seasonal allergic rhinoconjunctivitis. Allergy 2007, 62:1335-1338.
14. Keiding H., Jørgensen K.P. A cost-effectiveness analysis of immunotherapy with SQ allergen extract for patients with seasonal allergic rhinoconjunctivitis in selected European countries. Curr Med Res Opin 2007, 23:1113-1120.
15. 4 inhibitory antibody activity. J Allergy Clin Immunol 2008, 121:1120-1125.
16. Walker S.M., Pajno G.B., Lima M.T., et al. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. J Allergy Clin Immunol 2001, 107:87-93.
17. Justicia J.L., Barasona M.J., Serrano P., et al. Predicting patients at high-risk of systemic reactions to cluster allergen immunotherapy: a pilot prospective observational study. J Investig Allergol Immunol 2007, 17:386-392.
18. Ohashi Y., Nakai Y., Tanaka A., et al. Risk factors for adverse systemic reactions occurring during immunotherapy with standardized Dermatophagoides farinae extracts. Acta Otolaryngol Suppl 1998, 538:113-117.
19. Winther L., Malling H.J., Mosbech H. Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis. II. Side-effects. Allergy 2000, 55:827-835.
20. Mothes N., Heinzkill M., Drachenberg K.J., et al. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy 2003, 33:1198-1208.
21. Nouri-Aria K.T., Wachholz P.A., Francis J.N., et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 2004, 172:3252-3259.
22. Pfaar O., Urry Z., Robinson D.S., et al. A randomized placebo-controlled trial of rush preseasonal depigmented polymerized grass pollen immunotherapy. Allergy 2012, 67:272-279.
23. 4 correlate closely with clinical response to grass pollen immunotherapy. Allergy 2012, 67:217-226.
24. Zenner H.P., Baumgarten C., Rasp G., et al. Short-term immunotherapy: a prospective, randomized, double-blind, placebo-controlled multicenter study of molecular standardized grass and rye allergens in patients with grass pollen-induced allergic rhinitis. J Allergy Clin Immunol 1997, 100:23-29.